ESC 365 - Continued vs. interrupted oral anticoagulation in patients with atrial fibrillation undergoing transfemoral transcatheter aortiv valve implantation

ESC Premium Access

Continued vs. interrupted oral anticoagulation in patients with atrial fibrillation undergoing transfemoral transcatheter aortiv valve implantation

Session: Maintenance of anti-thrombotic therapy after TAVI

Topic: Aortic Valve Intervention

Speaker: Doctor N. Mangner (Dresden, DE)

Event: ESC Congress 2018

Congress Presentation

Add to my library

About the speaker

Doctor Norman Mangner

Heart Centre Dresden - Dresden Technical University Hospital, Dresden (Germany)

1 presentation

0 follower

4 more presentations in this session

TAVI thrombosis - Current knowledge

Speaker: Professor A. Finkelstein (Tel-Aviv, IL)

Type of oral anticoagulants and outcomes after transcatheter aortic valve implantation

Speaker: Doctor D. Jochheim (Hattingen, DE)

Comparison of safety and benefits between single vs. dual antiplatelet therapy in patients undergoing transcatheter bioprosthetic aortic valve replacement: a meta-analysis

Speaker: Doctor S. Javed (The Bronx, US)

Anti-thrombotic therapy after TAVI - State of the art

Speaker: Professor R. Kornowski (Petah Tikva, IL)

Access the full session

Maintenance of anti-thrombotic therapy after TAVI

Speakers: Doctor N. Mangner, Professor A. Finkelstein, Doctor D. Jochheim, Doctor S. Javed, Professor R. Kornowski

About the event

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources